



Information on total number of voting rights and shares composing the share capital as at March 31, 2022

Paris, April 1, 2022 – 6.00PM CEST - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces the evolution of its share capital. The number of voting rights and shares composing its share capital as at March 31, 2022 is as follow:

Total voting rights	Total number of shares composing capital
Total real voting rights ⁽¹⁾ : 58,598,013	58,695,133 ⁽³⁾
Total theoretical voting rights ⁽²⁾ : 58,695,133	

(1): The actual (or net) voting rights correspond to the total number of voting rights exercisable at General Meetings. They are calculated based on the total number of voting rights attached to the total number of shares, less any shares without voting rights (treasury shares, etc.).

(2): Theoretical (or gross) voting rights include all voting rights attached to the shares (including those without voting rights).

(3): Including 665,000 new shares in accordance with the contract of Equity Line financing cancelled on November 6, 2019; and 12,533,034 new shares from conversion of ORNAN2019 by ESGO Fund.

Contacts

Pixium Vision

Offer Nonhoff

Chief Financial Officer

investors@pixium-vision.com

Media Relations

LifeSci Advisors

Sophie Baumont

sophie@lifesciadvisors.com

+33 6 27 74 74 49

Investor Relations

LifeSci Advisors

Guillaume van Renterghem

gvanreterghem@lifesciadvisors.com

+41 76 735 01 31

ABOUT PIXIUM VISION

Pixium Vision's mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period.

Pixium Vision is conducting clinical feasibility studies of its Prima system, its miniaturised wireless sub-retinal implant, in patients who have lost their sight due to retinal degeneration associated with the dry form of Age-Related Macular Degeneration (AMD). Pixium Vision works closely with world-renown academic partners, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, and UPMC in Pittsburgh, USA. The company is EN ISO 13485 certified. Pixium Vision has been qualified as an "Innovative Company" by Bpifrance.

For more information: <http://www.pixium-vision.com/fr>

Follow us on [@PixiumVision](https://twitter.com/PixiumVision); www.facebook.com/pixiumvision

[LinkedIn](https://www.linkedin.com/company/pixium-vision) www.linkedin.com/company/pixium-vision



Pixium Vision is listed on Euronext Growth Paris.

ISIN: FR0011950641; Mnemonic: ALPIX

Pixium Vision is included in the Euronext GROWTH ALLSHARE index

Pixium Vision shares are eligible for the French PEA-PME and FCPI investment vehicles.

Disclaimer

This press release, implicitly or expressly, contains certain forward-looking statements concerning Pixium Vision and its business. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, financial conditions, performance or achievements of Pixium Vision to be materially different from the results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Pixium Vision issues this press release as at this date and does not undertake to update any forward-looking statements contained herein, whether in response to new information, future events or otherwise. For a description of the risks and uncertainties that could cause the actual results, financial conditions, performance or achievements of Pixium Vision to differ from those contained in the forward-looking statements, please refer to section 3 "Risk Factors" of the Company's 2019 Universal Registration Document, which was filed with the Autorité des Marchés Financiers under number D.20-0350 on 24 April 2020, and which can be viewed on the websites of the Autorité des Marchés Financiers - "AMF" (www.amf-france.org) and Pixium Vision (www.pixium-vision.com) and in the Financial Report for the 2020 financial year (Appendix 1), available free of charge on the Pixium Vision website (www.pixium-vision.com)